RIMONABANT ACCEPTED FOR FILING BY THE FDA
RIMONABANT ACCEPTED FOR FILING BY THE FDA Paris, France - June 23, 2005 - Sanofi-aventis announced today that the United States Food and Drug Administration (FDA) has accepted for filing the company’s New Drug Application (NDA) for rimonabant, the first agent in a new therapeutic class known as selective cannabinoid type 1 (CB1) blockers. Rimonabant, discovered and developed by sanofi-aventis, is thought to represent a new approach for the comprehensive management of cardiovascular risk factors. The compound has been studied to date in over 6,500 overweight and obese adults for up to 2